Literature DB >> 1850665

Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

M Abdulatif1, M Naguib.   

Abstract

Neostigmine 0.06 mg.kg-1 or edrophonium 1 mg.kg-1 were administered to two groups of 15 patients each for antagonism of pipecuronium-induced neuromuscular block at 20% spontaneous recovery of the first twitch (T1) of the train-of-four (TOF) stimulation. The mean onset of action (+/-SEM) of edrophonium (18.1 +/- 2.4 sec) was significantly more rapid (P less than 0.01) than that of neostigmine (47.6 +/- 4 sec), as were the times taken to attain a TOF ratio of 0.25 and 0.5. Nevertheless, the reversal time (time taken from the end of injection of the antagonist until TOF ratio value had reached 0.75) was significantly shorter (P less than 0.01) in the neostigmine than in the edrophonium group (499.3 +/- 62 vs 767 +/- 52 sec respectively). The TOF ratio ten minutes after reversal was greater in the neostigmine group than in the edrophonium group (P less than 0.01), 0.78 +/- 0.02 vs 0.68 +/- 0.02 min respectively. At that time, 33% (5 out of 15) and 80% (12 out of 15) patients failed to be reversed adequately (TOF ratio of 0.75) after neostigmine 0.06 mg.kg-1 and edrophonium 1 mg.kg-1, respectively. Administration of one additional dose (one-third of the initial dose) of the same antagonist resulted in adequate antagonism in the remaining five patients in the neostigmine group and in nine patients in the edrophonium group. Two such doses were required in the remaining three patients in the latter group. The mean total dose of neostigmine and edrophonium employed in this study was 0.067 +/- 0.002 and 1.3 +/- 0.05 mg.kg-1, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850665     DOI: 10.1007/BF03008137

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  22 in total

Review 1.  Clinical assessment of neuromuscular transmission.

Authors:  J Viby-Mogensen
Journal:  Br J Anaesth       Date:  1982-02       Impact factor: 9.166

2.  Recovery characteristics following antagonism of atracurium with neostigmine or edrophonium.

Authors:  R M Jones; A C Pearce; J P Williams
Journal:  Br J Anaesth       Date:  1984-05       Impact factor: 9.166

3.  Edrophonium and neostigmine for reversal of the neuromuscular blocking effect of vecuronium.

Authors:  J Engbaek; H Ording; D Ostergaard; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  1985-07       Impact factor: 2.105

4.  Clinical experiences with pipecuronium bromide.

Authors:  M Boros; J Szenohradszky; A Kertész; G Marosi; L Tutsek
Journal:  Acta Chir Hung       Date:  1983

5.  Relationship of train-of-four ratio to twitch depression during pancuronium-induced neuromuscular blockade.

Authors:  G G Graham; R Morris; D A Pybus; T A Torda; R Woodey
Journal:  Anesthesiology       Date:  1986-12       Impact factor: 7.892

6.  Comparative clinical study of pipecurium bromide and pancuronium bromide.

Authors:  M Boros; J Szenohradszky; G Marosi; I Tóth
Journal:  Arzneimittelforschung       Date:  1980

7.  Pharmacological study of a new competitive neuromuscular blocking steroid, pipecurium bromide.

Authors:  E Kárpáti; K Biró
Journal:  Arzneimittelforschung       Date:  1980

8.  Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium.

Authors:  A Ferguson; P Egerszegi; D R Bevan
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

9.  Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia.

Authors:  R Cronnelly; R B Morris; R D Miller
Journal:  Anesthesiology       Date:  1982-10       Impact factor: 7.892

10.  Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium.

Authors:  S M Rupp; J W McChristian; R D Miller; J A Taboada; R Cronnelly
Journal:  Anesthesiology       Date:  1986-06       Impact factor: 7.892

View more
  6 in total

1.  The current status of edrophonium: have we come "full circle"?

Authors:  A F Kopman
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

Review 2.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 3.  Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.

Authors:  R K Mirakhur
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

4.  Neuromuscular effects of pipecuronium during sevoflurane anesthesia compared with isoflurane and enflurane anesthesia.

Authors:  Y Nakao; M Ohno; M Imai; O Kemmotsu
Journal:  J Anesth       Date:  1993-10       Impact factor: 2.078

5.  Edrophonium priming alters the course of neuromuscular recovery from a pipecuronium neuromuscular blockade.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

Review 6.  New developments in nondepolarizing muscle relaxants.

Authors:  R K Mirakhur
Journal:  Yale J Biol Med       Date:  1993 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.